Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SwitzerlandIPO:
19 October 2016Website:
http://www.crisprtx.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 23 Nov 2024 00:55:36 GMTDividend
Analysts recommendations
Institutional Ownership
CRSP Latest News
On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies.
3 Monster Stocks in the Making
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here.
Where Will CRISPR Therapeutics Be in 3 Years?
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT.
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals.
CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago.
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada-
What type of business is CRISPR Therapeutics AG?
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
What sector is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG is in the Healthcare sector
What industry is CRISPR Therapeutics AG in?
CRISPR Therapeutics AG is in the Biotechnology industry
What country is CRISPR Therapeutics AG from?
CRISPR Therapeutics AG is headquartered in Switzerland
When did CRISPR Therapeutics AG go public?
CRISPR Therapeutics AG initial public offering (IPO) was on 19 October 2016
What is CRISPR Therapeutics AG website?
https://www.crisprtx.com
Is CRISPR Therapeutics AG in the S&P 500?
No, CRISPR Therapeutics AG is not included in the S&P 500 index
Is CRISPR Therapeutics AG in the NASDAQ 100?
No, CRISPR Therapeutics AG is not included in the NASDAQ 100 index
Is CRISPR Therapeutics AG in the Dow Jones?
No, CRISPR Therapeutics AG is not included in the Dow Jones index
When was CRISPR Therapeutics AG the previous earnings report?
No data
When does CRISPR Therapeutics AG earnings report?
The next expected earnings date for CRISPR Therapeutics AG is 21 February 2025